TGFTX4



NAME OF DRUG : TGFTX4

ALSO KNOWN AS : TGFTX4

LABORATORY : GENFIT

STATUS AND ADVANCEMENT

Type of drug : ?

Clinical trials advancement : Preclinic

Estimated time to market : 136 months.

LABORATORY ABSTRACT ON THE DRUG

We have identified a proprietary series of compounds that inhibit both the proliferation and the pro-fibrotic activation of primary human Hepatic Stellate Cells (HSCs) with high efficacy. The anti-fibrotic properties of this compound series were also confirmed in vivo, in well established liver fibrosis models. In parallel, we have identified a group of molecular targets, including Receptor Tyrosine Kinases (RTKs), that explain the anti-fibrotic properties of the TGFTX4 series. We are currently working on a hit to lead optimization program to design high quality drug candidates for development in fibrotic liver diseases.

RECENT NEWS ON TGFTX4

SOME PUBLICATIONS RELATED WITH TGFTX4

SOME NASHBIOTECHS POINTS OF VIEW RELATED WITH TGFTX4


WWW.NASHBIOTECHS.COM  -  Copyright G DIVRY 2015-2016  - Contact and TERMS OF USE